By Tony Winterburn • Published: 04 Jun 2020 • 13:28
TAKING hydroxychloroquine, Donald Trumps Covid-19 drug of choice, after being exposed to someone with Covid-19, does not protect someone from getting the disease.
That’s the conclusion of a study published yesterday involving 821 participants. All had direct exposure to a Covid-19 patient, either because they lived with one, or were a health care provider or first responder.
The study had an unusual design. “It was all web-based,” says Radha Rajasingham, an infectious disease physician at the University of Minnesota. “People would go to our website if they were interested in enrolling.”
People given hydroxychloroquine were more likely to report side-effects such as nausea and stomach pain – 40 per cent v 17 per cent. But there were no serious reactions and no heart rhythm disturbances, which is a known issue with the drug.
“While we had hoped this drug would work in this context, our study demonstrates that hydroxychloroquine is no better than a placebo when used as post-exposure prophylaxis within four days of exposure to someone infected with the new coronavirus,” said Dr Todd Lee, an associate professor of medicine, division of infectious diseases at McGill University in Canada and one of the lead authors of the study.
Share this story
Subscribe to our Euro Weekly News alerts to get the latest stories into your inbox!
By signing up, you will create a Euro Weekly News account if you don't already have one. Review our Privacy Policy for more information about our privacy practices.
Share your story with us by emailing newsdesk@euroweeklynews.com, by calling +34 951 38 61 61 or by messaging our Facebook page www.facebook.com/EuroWeeklyNews
By signing up, you will create a Euro Weekly News account if you don’t already have one. Review our Privacy Policy for more information about our privacy practices.
Download our media pack in either English or Spanish.